首页 | 本学科首页   官方微博 | 高级检索  
检索        


Variability of morphine disposition during long-term subcutaneous infusion in terminally ill cancer patients
Authors:A Vermeire  J P Remon  M T Rosseel  F Belpaire  J Devulder  M G Bogaert
Institution:(1) Laboratory of Pharmaceutical Technology, School of Pharmacy, University of Gent, Gent, Belgium, BE;(2) Heymans Institute of Pharmacology, University of Gent Medical School, De Pintelaan 185, B-9000 Gent, Belgium Tel.+32 9 240 33 36; Fax+32 9 240 49 88, BE;(3) Pain Clinic, University Hospital, University of Gent, Gent, Belgium, BE
Abstract:Objective: To study the plasma concentrations of morphine and its glucuronides to assess the intra- and interindividual variability of the disposition of morphine administered by subcutaneous infusion in cancer patients. Methods: Blood samples were taken repeatedly in eight patients with severe cancer pain who were being treated with morphine (60–3000 mg per day) via chronic (8–160 days) subcutaneous infusion. Venous blood samples were collected at least weekly and, when possible, on 3 consecutive days after dose adaptation or any other major change in the patients' treatment. Concentrations of morphine and its glucuronides in plasma were measured after solid-phase extraction using a validated high-performance liquid chromatography assay. The stability of the morphine solutions was determined by repeated measurement of the concentrations of morphine and its degradation products in the solutions. Results: The morphine concentration in the infusion solutions remained unchanged during storage and infusion. The plasma concentrations of morphine and its glucuronides were within the ranges reported in the literature. There was, as expected, a large interindividual variability: from patient to patient, the mean of the normalised plasma concentrations ranged from 0.3 ng · ml−1 · mg−1 to 0.8 ng · ml−1 · mg−1 for morphine, from 1.0 ng · ml−1 · mg−1 to 3.1 ng · ml−1 · mg−1 for morphine-6-glucuronide and from 6.8 ng · ml−1 · mg−1 to 24.3 ng · ml−1 · mg−1 for morphine-3-glucuronide. Intraindividual variability was also important. The residual standard deviation of the mean normalised plasma concentrations calculated for each patient ranged from 26% to 56% for morphine, from 20% to 51% for morphine-6-glucuronide and from 20% to 49% for morphine-3-glucuronide. The normalised plasma concentrations of morphine and its glucuronides did not increase with dose or time, and no explanation for the pronounced pharmacokinetic intraindividual variability was found. Conclusion: During subcutaneous infusion of morphine, there is a large intra- and interindividual variability of the morphine disposition which could be of clinical relevance. Received: 5 August 1997 / Accepted in revised form: 8 October 1997
Keywords:Morphine disposition  Cancer patients  Subcartaneous infusion
本文献已被 SpringerLink 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号